## Alkem Laboratories Limited (ALKEM) Stock Analysis - December 20, 2024

This report analyzes Alkem Laboratories Limited (ALKEM) stock data to provide a buy, sell, or hold recommendation.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | ALKEM                    |
| Company Name     | Alkem Laboratories Limited |
| Industry         | Pharmaceuticals           |
| Listing Date     | 2015-12-23                |
| ISIN             | INE540L01014              |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|-----------|
| Last Price            | 5,425.00  |
| Change                | -69.25    |
| % Change              | -1.26%    |
| Previous Close        | 5,494.25  |
| Open                  | 5,535.00  |
| Close                 | 5,427.50  |
| VWAP                  | 5,468.69  |
| Week High             | 6,439.90  |
| Week Low              | 4,407.05  |
| Sector PE             | 29.68     |
| Symbol PE             | 30.40     |
| Total Traded Volume   | 1.13      | (in unspecified units, likely millions)
| Delivery Quantity     | 56,981    | (in unspecified units)
| Delivery to Traded % | 50.38%    |
| CM Daily Volatility   | 1.56%     |
| CM Annual Volatility  | 29.80%    |


**1.3 Pre-Open Market Data:**

The pre-open market showed a slightly higher opening price (5,535.00) compared to the previous close (5,494.25), but the final price was lower than the pre-open IEP (5,535.00).  This suggests some selling pressure during the opening.

**1.4 Corporate Actions:**

The following dividends have been declared:

| Ex-Date      | Purpose                                      | Amount (Rs) |
|--------------|----------------------------------------------|-------------|
| 09-Aug-2024  | Dividend                                      | 5           |
| 16-Feb-2024  | Interim Dividend                             | 35          |
| 10-Aug-2023  | Dividend                                      | 10          |
| 17-Feb-2023  | Interim Dividend & Special Dividend           | 40          |
| 08-Aug-2022  | Dividend                                      | 4           |
| 10-Feb-2022  | Interim Dividend                             | 30          |
| 09-Aug-2021  | Dividend                                      | 5           |
| 11-Feb-2021  | Interim Dividend                             | 25          |


**1.5 Recent Announcements:**

Several announcements were made, including newspaper publications, acquisition details, general updates, and analyst/institutional investor meetings.  Specific details require further investigation from the provided links.

**1.6 Financial Results (Last Five Quarters):**

| Quarter End    | Income (Rs)  | Expenditure (Rs) | Profit After Tax (Rs) | EPS (Rs) |
|----------------|---------------|--------------------|-----------------------|----------|
| 30-Sep-2024    | 299,216       | 222,449            | 69,758                | 58.34    |
| 30-Jun-2024    | 260,620       | 196,526            | 58,325                | 48.78    |
| 31-Mar-2024    | 244,916       | 204,763            | 32,497                | 27.18    |
| 31-Dec-2023    | 259,025       | 200,456            | 50,423                | 42.17    |
| 30-Sep-2023    | 269,643       | 205,771            | 64,651                | 54.07    |


**1.7 Shareholding Patterns:**

| Quarter End    | Promoter & Promoter Group (%) | Public (%) |
|----------------|-----------------------------|------------|
| 30-Sep-2024    | 55.66                         | 44.34      |
| 30-Jun-2024    | 56.38                         | 43.62      |
| 31-Mar-2024    | 56.74                         | 43.26      |
| 31-Dec-2023    | 56.74                         | 43.26      |
| 30-Sep-2023    | 56.74                         | 43.26      |

Promoter holdings have decreased slightly over the past year.


**1.8 Board Meetings:**

Several board meetings were held to discuss financial results and dividend announcements.


**1.9 Key Management Personnel:**

The provided data lists several directors, including the Chairperson, Executive Directors, and Independent Directors.  Specific details are available in the data.


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price is below the previous close, open, and pre-open IEP, indicating downward pressure. However, it's above the week's low.

**2.2 Financial Performance:**

Revenue and profit after tax show some fluctuation but generally positive trends over the last five quarters. EPS also shows a generally positive trend, although there was a dip in Q4 2024.

**2.3 Shareholding Analysis:**

A slight decrease in promoter holdings is observed over the past year, which could be a cause for concern, but the decrease is not drastic.

**2.4 Corporate Action Summary:**

Consistent dividend payments indicate a healthy financial position.

**2.5 Volatility and Risk:**

The CM Daily and Annual Volatility are relatively high (1.56% and 29.80% respectively), suggesting higher risk.

**2.6 Key Directors and Contact Info:**

Contact information for Alkem Laboratories Limited is available in the provided data.


**3. Final Verdict:**

**Hold.**

**Reasoning:**

While Alkem Laboratories Limited shows generally positive financial performance with consistent dividend payouts, the recent downward price movement, high volatility, and slight decrease in promoter holdings raise some concerns.  The relatively high volatility suggests a higher risk profile.  More information is needed regarding the recent announcements to fully assess their impact.  Given the current data, a "Hold" recommendation is the most prudent course of action until further information clarifies the recent price drop and the implications of the announcements.

**Conclusion:**

Based on the provided data, Alkem Laboratories Limited presents a mixed picture.  While the company demonstrates financial strength through consistent profitability and dividend payments, the recent price decline and high volatility warrant a cautious approach.  Further investigation into recent announcements and a closer examination of the reasons behind the declining promoter holdings are recommended before considering a buy decision.
